Tevogen.AI's PredicTcell™ Beta Shows Improved Precision, Expanding Drug Discovery Capabilities
TVGN is trading near its 52-week low of $6.218 (13% above the low).
Summary
Tevogen.AI announced significant advancements in its PredicTcell™ Beta AI model, reporting improved recall from 87% to 92% and precision from 40% to 48%. The company has also expanded its proprietary peptide database to over 655 million sequences, representing nearly 16 billion data points. This development is crucial for Tevogen's strategy to accelerate drug discovery, reduce development costs, and increase the probability of clinical success by enhancing target prediction. This positive update on a core technology platform follows recent news regarding the TVGN 489 program and ongoing M&A evaluations, highlighting the company's active pursuit of growth and innovation. Investors should watch for further integration of this AI into their pipeline and potential pharmaceutical partnerships.
At the time of this announcement, TVGN was trading at $7.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.5M. The 52-week trading range was $6.22 to $75.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.